Flumazenil
BP/EP/USP
USDMF No. 17971, USFDA Approved, CEP: R1-CEP2008-121-Rev01, UK GMP, Stability Studies In Zone IVB
Technical Data
| M. Wt | 303.29 |
| Formula | C15H14FN3O3 |
| CAS Number | 78755-81-4 |
| PubChem ID | 3373 |
| InChI Key | OFBIFZUFASYYRE-UHFFFAOYSA-N |
| Smiles | CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1 |
| Documents | CEP, USFDA Approved, USDMF |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Description
Flumazenil is an imidazo-benzodiazepine derivative, effective in reversing benzodiazepine-induced activities. Flumazenil antagonizes the benzodiazepine binding site of the gamma-aminobutyric acid (GABA)/benzodiazepine receptor complex in the central nervous system (CNS), thereby preventing the chloride channel opening events and inhibiting neuronal hyperpolarization. As a result, flumazenil reverses benzodiazepine-induced effects including sedation, psychomotor deficits, amnesia, and hypoventilation in a dose-dependent manner.
Synonyms
Flumazenil, Flumazenilo, Flumazenilum, Flumazepil, Flumazenilo, Romazicon, Anexate, Mazicon, Lanexat, ethyl 8-fluoro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
Disclaimer
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1)
